Abstract
As a first trial for in vivo imaging of β-secretase (BACE1) in Alzheimer's disease brain, we applied a novel non-peptidergic small molecule which has high affinity to the enzyme, naphthalene-1-carboxylic acid (3'-chloro-4'-fluoro-4-piperazin-1-yl-biphenyl-3-yl)amide (NCFB) into positron emission tomography (PET) probe. In the current study, N-(11)C-methylated compound of NCFB, [(11)C]Me-NCFB was synthesized and evaluated for the visualization of BACE1 in brain. BACE1 inhibitory constant was measured by FRET assay. [(11)C]Me-NCFB was synthesized from NCFB with [(11)C]methyl triflate. To evaluate properties of [(11)C]Me-NCFB, log P value, stability in mouse plasma and brain uptake index were measured. The biodistribution in 6-week-old ddY mice was also studied. BACE1 inhibitory constant showed an affinity of Me-NCFB to the enzyme (IC50=2.3 ± 0.80 μM). [(11)C]Me-NCFB was synthesized in a 3.0% ± 0.55% decay-corrected radiochemical yield. [(11)C]Me-NCFB showed high lipophilicity, high stability in mouse plasma and blood-brain barrier (BBB) permeability. Injected to 6-week-old ddY mice, [(11)C]Me-NCFB penetrated BBB and was retained in the brain (0.79% ± 0.22% ID/g at 2 min and 0.75% ± 0.08% ID/g at 60 min after injection, respectively), moreover, rapid blood clearance was observed. [(11)C]Me-NCFB could have a potential as a PET probe for the imaging of BACE1 in the brain.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
